Cutting-edge studies unveil new mechanisms pertinent to Alzheimer’s disease and related neurodegenerative conditions. Aarhus University researchers identified defects in exosome production linked to familial Alzheimer’s mutations, implicating impaired neuronal communication. Remynd NV reported positive Phase IIa data for REM-127, a novel agent restoring neuronal calcium homeostasis and reducing pathological tau protein. Nanonewron secured NIH funding to develop TNF-α inhibitors targeting neuroinflammation. These advances underscore the multifaceted therapeutic strategies emerging for Alzheimer’s disease.